Tecan Group AG · SIX:TECN

Tecan — FY2020 Earnings Presentation

29 slides from Tecan's earnings presentation, Mar 16, 2021

  1. Slide 1: Full Year Results 2020

    Zurich, March 16 2021 Full Year Results 2020 ANALYST & MEDIA CONFERENCE CALL

  2. Slide 2: Speakers

    Speakers Dr. Achim von Leoprechting, CEO Tania Micki, CFO

  3. Slide 3: Agenda

    Agenda FINANCIAL AND OPERATING HIGHLIGHTS FINANCIAL RESULTS OUTLOOK QUESTIONS AND ANSWERS 3

  4. Slide 4: Financial Highlights 2020

    Financial Highlights 2020 • Extraordinary demand for COVID-19 related products • Surge in orders, with order entry up by 38.5% in LC and 33.9% in CHF; order backlog at record high • Sales growth of +18.7% in LC and +14.8% in CHF; acceleration in H2 • Double-digit sales growth in in both business seg

  5. Slide 5: Operating Highlights 2020

    Operating Highlights 2020 • Health and safety of Tecan employees prioritized THERMO FISHER SCIENTIFIC AMPLITUDE SOLUTION during the coronavirus pandemic • Global manufacturing and business operations secured for undisrupted support of customers • Responded to unprecedented shifts and surge in demand

  6. Slide 6: Tecan at the Forefront of the Fight Against COVID-19

    Tecan at the Forefront of the Fight Against COVID-19 CONTRIBUTIONS TO THE GLOBAL EFFORTS TO CONTAIN THE PANDEMIC NOT A COINCIDENCE FROM VACCINE DEVELOPMENT TO CLINICAL TESTING • Corporate strategy and core competencies provided the basis for fast and flexible response • Application focus on genomics

  7. Slide 7: Tecan at the Forefront of the Fight Against COVID-19

    Tecan at the Forefront of the Fight Against COVID-19 WE ARE PASSIONATE ABOUT SUPPORTING AND EMPOWERING LABS AND DIAGN OSTIC COMPANIES LIFE SCIENCES BUSINESS PARTNERING BUSINESS Supporting and equipping individual labs and Supplying in vitro diagnostic companies with lab chains to further scale up CO

  8. Slide 8: Robotic Pipette Tips: a Seemingly Simple Product

    Robotic Pipette Tips: a Seemingly Simple Product FULLY AUTOMATED PRODUCTION LINES, PRECISE MOLDING, INLINE VISUAL QUALITY TESTING • In this unprecedented time, Tecan recognized its responsibility to enable the scale-up of diagnostic testing • Increase in global manufacturing capacity, resulting in a

  9. Slide 9: Agenda

    Agenda FINANCIAL AND OPERATING HIGHLIGHTS FINANCIAL RESULTS OUTLOOK QUESTIONS AND ANSWERS 9

  10. Slide 10: 2020 Order Entry and Sales Performance

    2020 Order Entry and Sales Performance ORDER ENTRY FY 2020 ORDER ENTRY 2020 VS. 2019 900 855.2 • +33.9% in CHF and +38.5% in LC 800 • Orders surged for product lines supporting the global fight CHF (mio) 700 638.6 against COVID-19 (instruments and consumables) 600 • Significantly exceeded the sales

  11. Slide 11: 2020 Segment Sales

    2020 Segment Sales SALES LIFE SCIENCES BUSINESS: 408.8 2019 420 FY • Sales +13.2% in CHF and +18.7% in LC 2020 380 361.2 • Strong demand for products supporting the COVID-19 response (automation workstations and pipette tips) CHF (mio) 340 322.1 • Other parts experienced slowdown (detection instrume

  12. Slide 12: FY 2020 Regional Sales Development

    FY 2020 Regional Sales Development YoY % +44.3% in LC EUROPE +39.8% in CHF Others • Growth driven by Life Sciences Business with instruments and YoY % 2.0% consumables for PCR-based COVID-19 testing +22.7% in LC • Sales of Partnering Business suffered from lower volumes in +17.5% in CHF routine diag

  13. Slide 13: FY 2020 Gross Profit

    FY 2020 Gross Profit GROSS PROFIT (% = % OF SALES) GROSS PROFIT INCREASED TO CHF 354.9 360 354.9 • CHF 57.6m or 19.4% above 2019 GROSS PROFIT MARGIN UP BY 190 BPS Main effects contributing: 320 • (+) Product mix, despite a higher consumable contribution CHF (mio) 297.3 • (+) Price • (-) Underabsorpt

  14. Slide 14: FY 2020 Cost Structure

    FY 2020 Cost Structure OPERATING EXPENSES (% = % OF SALES) 233.9m OPERATING EXPENSES GREW LESS THAN SALES 240 (32.0%) 209.4m • Total operating expenses down by 90 bps, 220 (32.9%) driven by economies of scale 200 105.9 180 • Sales & Marketing increased slightly less than sales despite 92.9 (14.5%) (

  15. Slide 15: FY 2020 Reported EBIT and EBITDA

    FY 2020 Reported EBIT and EBITDA EBIT AND EBITDA 159.1 2019 EBITDA GREW TO CHF 159.1M 160 140 2020 • CHF 36.3m or 29.6% above 2019 121.4 122.8 CHF (mio) 120 • (+) Improved gross profit margin (+190 bps) 100 88.7 • (+) More development costs were capitalized 80 • (+) Adjustment of Swiss pension plan

  16. Slide 16: FY 2020 Segment Profitability

    FY 2020 Segment Profitability EBIT (IN CHF MILLIONS) 78.2 2019 LIFE SCIENCES BUSINESS: 80 2020 70 56.7 59.1 • EBIT margin increased to 17.4% 60 46.2 • Factors contributing include: CHF (mio) 50 40 30 • (+) Volume effect 20 • (+) Margin contribution from consumables business 10 0 • (+) Lower net R&D

  17. Slide 17: FY 2020 Net Profit

    FY 2020 Net Profit NET PROFIT NET PROFIT GREW MORE THAN EBIT 110 • CHF 30.5m or 41.7% above 2019 103.7 100 NET PROFIT MARGIN INCREASED TO 14.2% • Main factor contributing: 90 • (+) EBIT up by CHF 32.7m CHF (mio) 80 • (+) Improved financial result 73.2 • (-) Tax rate of 12.3% (2019: 11.6%) 70.7 70 65

  18. Slide 18: FY 2020 Basic Earnings per Share

    FY 2020 Basic Earnings per Share BASIC EARNINGS PER SHARE EARNINGS PER SHARE INCREASED TO CHF 8.69 9 8.69 NUMBER OF SHARES OUTSTANDING: 8 12.0M (2019: 11.9M) INCREASE IN THE DIVIDEND FROM CHF 2.20 CHF / share 7 TO CHF 2.30 PER SHARE TO BE PROPOSED 6.02 6.18 TO ANNUAL GENERAL MEETING 6 5.67 48.8% 49.

  19. Slide 19: FY 2020 Cash Flow

    FY 2020 Cash Flow +208.3 -288.7 266.3 -37.4 148.4 Cash at end From Operations From Investments From Financing Cash at end of December 2019 of December 2020 CASH FLOW FROM OPERATIONS OF CHF 208.3M (2019: CHF 98.8M)  Cash conversion of 28.5 % of sales (2019: 15.5%)  Days Sales Outstanding down to 42

  20. Slide 20: FY 2020 Key Figures

    FY 2020 Key Figures 2019 2020 Δ IN % Order Entry (in CHF mio) 638.6 855.2 +33.9% Sales (in CHF mio) 636.8 730.9 +14.8% Sales in local currencies (in CHF mio) 615.7 730.9 +18.7% Gross Profit (in CHF mio) 297.3 354.9 +19.4% in % of sales 46.7% 48.6% R&D (in CHF mio) 59.9 62.0 +3.7% in % of sales 9.4%

  21. Slide 21: Agenda

    Agenda FINANCIAL AND OPERATING HIGHLIGHTS FINANCIAL RESULTS OUTLOOK QUESTIONS AND ANSWERS 21

  22. Slide 22: Life Sciences Business: Products Already Launched in 2021

    Life Sciences Business: Products Already Launched in 2021 NEW SOLUTIONS FOCUSED ON APPLICATION-SPECIFIC NEEDS – ADDITIONAL LAUNCHES ANTICIPATED FLUENT MIX AND PIERCE WORKSTATION THE FRIDA READER MODULE FOR FLUENT • End-to-end automation for whole blood pipetting in clinical • Expanding Tecan’s cutti

  23. Slide 23: Partnering Business: Production Ramp Up and New Launches

    Partnering Business: Production Ramp Up and New Launches PARTNER OF CHOICE TO THE IN-VITRO DIAGNOSTICS INDUSTRY RAMP UP FOR PRODUCTS ALREADY IN SUPPLY PHASE NEW LAUNCHES IN THE NEXT 12 MONTHS PS-10 Sample Prep System for flow cytometry Tecan Cavro Air Displacement Integrated analyzer using MALDI mas

  24. Slide 24: 2021 Still Impacted by COVID-19

    2021 Still Impacted by COVID-19 HOW LONG AND HOW MUCH THOUGH? PCR-BASED COVID-19 TESTING IN THE US FACTORS IMPACTING COVID-19 TESTING IN 2021 • Duration and magnitude of elevated levels of 60 55 58.4 PCR-based testing for acute COVID-19 infections • Impact on continued build out of test infrastructu

  25. Slide 25: Financial Outlook for 2021

    Financial Outlook for 2021 SALES DEVELOPMENT OUTLOOK 2021 Growth in • Based on high order backlog and continued elevated demand, MSD to 800 mid-teens very strong business performance expected for H1 730.9 range in 700 LC1 • Demand trends for COVID-19-related products are subject to greater 636.8 CHF

  26. Slide 26: Tecan is Well-Positioned for 2021 and Beyond

    Tecan is Well-Positioned for 2021 and Beyond STRENGTHENED POSITION AND BASIS FOR POST-PANDEMIC GROWTH • Tecan was well prepared to quickly re-focus capabilities on the fight against COVID-19 • Year 2020 also illustrated resilience of business and confirmed the strategic priorities • Significant oppo

  27. Slide 27: Connecting. Q&A.

  28. Slide 28: Contact and Events

    Contact and Events CONTACT Martin Braendle Senior Vice President, Corp. Communications & IR Phone: +41 (0) 44 922 84 30 investor@tecan.com www.tecan.com NEXT EVENTS 2021 April 13: Annual Shareholder Meeting August 18: Half Year Results 2021 28

  29. Slide 29: Tecan – Who we are

    Tecan – Who we are Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the lif

Tecan Group — FY2020 Earnings Presentation on 6ix